Company profile
Ticker
ORKA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
APOGEE ENTERPRISES INC
SEC CIK
Corporate docs
IRS number
363855489
ORKA stock data
Analyst ratings and price targets
Latest filings (excl ownership)
DEF 14A
Definitive proxy
18 Oct 24
PRE 14A
Preliminary proxy
7 Oct 24
8-K
Departure of Directors or Certain Officers
4 Oct 24
8-K
Oruka Therapeutics Announces $200 Million Private Placement
13 Sep 24
8-K
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5 Sep 24
425
Business combination disclosure
26 Aug 24
8-K
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
26 Aug 24
8-K
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
23 Aug 24
425
Business combination disclosure
16 Aug 24
8-K
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
16 Aug 24
Latest ownership filings
SC 13G
FMR LLC
7 Oct 24
SC 13D/A
Fairmount Funds Management LLC
13 Sep 24
4
Peter Evan Harwin
13 Sep 24
SC 13D
Fairmount Funds Management LLC
6 Sep 24
3
Peter Evan Harwin
6 Sep 24
3
Cameron Turtle
6 Sep 24
3
Samarth Kulkarni
6 Sep 24
3
Carl Dambkowski
6 Sep 24
3
KRISTINE M BALL
6 Sep 24
3
Paul T Quinlan
6 Sep 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.28 mm | 33.28 mm | 33.28 mm | 33.28 mm | 33.28 mm | 33.28 mm |
Cash burn (monthly) | 873.33 k | 572.75 k | 1.04 mm | 760.92 k | 878.00 k | 573.92 k |
Cash used (since last report) | 3.19 mm | 2.09 mm | 3.80 mm | 2.78 mm | 3.21 mm | 2.10 mm |
Cash remaining | 30.09 mm | 31.19 mm | 29.48 mm | 30.50 mm | 30.07 mm | 31.19 mm |
Runway (months of cash) | 34.5 | 54.5 | 28.3 | 40.1 | 34.3 | 54.3 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Sep 24 | Fairmount Funds Management | Common Stock | Grant | Acquire A | Yes | No | 23 | 275,000 | 6.33 mm | 638,614 |
11 Sep 24 | Fairmount Funds Management | Series A Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 23000 | 160 | 3.68 mm | 160 |
29 Aug 24 | Jacob Ma-Weaver | Stock option Common stock | Other | Dispose J | No | No | 2.27 | 12,000 | 27.24 k | 0 |
29 Aug 24 | Jacob Ma-Weaver | Stock option Common stock | Other | Dispose J | No | No | 2.32 | 6,000 | 13.92 k | 0 |
29 Aug 24 | Jacob Ma-Weaver | Stock option Common stock | Other | Dispose J | No | No | 1.64 | 6,000 | 9.84 k | 0 |
News
Stifel Initiates Coverage On Oruka Therapeutics with Buy Rating, Announces Price Target of $49
11 Oct 24
Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
8 Oct 24
HC Wainwright & Co. Initiates Coverage On Oruka Therapeutics with Buy Rating, Announces Price Target of $45
7 Oct 24
Oruka Therapeutics Announced New Preclinical Data On ORKA-001, A Novel Extended Half-life Monoclonal Antibody Targeting IL-23p19, At The European Academy Of Dermatology And Venereology Congress
25 Sep 24
Leerink Partners Initiates Coverage On Oruka Therapeutics with Outperform Rating, Announces Price Target of $44
17 Sep 24
Press releases
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
25 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
12 Sep 24
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001's Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
12 Sep 24
ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split
29 Aug 24
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
26 Aug 24